Difference between revisions of "Obinutuzumab (GA101)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Redirected page to Obinutuzumab (Gazyva))
 
(2 intermediate revisions by one other user not shown)
Line 1: Line 1:
−
'''In clinical trials'''.  Also known as RO5072759, Afutuzumab.
+
#REDIRECT [[Obinutuzumab (Gazyva)]]
−
 
 
−
==General information==
 
−
Class/mechanism: Glyco-engineered anti-CD20 IgG1 type II monoclonal antibody.  Engineered with a modified elbow hinge residue (valine instead of leucine at Kabat position 11) and a glyco-engineered Fc region, which is postulated to enhance its immunomodulatory effect.<ref>Reichert JM. Antibody-based therapeutics to watch in 2011. MAbs. 2011 Jan-Feb;3(1):76-99. Epub 2011 Jan 1. [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3038014/ link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/21051951 PubMed]</ref>
 
−
<br>Route: IV
 
−
<br>Extravasation: no information
 
−
 
 
−
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer.  Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert.
 
−
 
 
−
==Diseases for which it is used==
 
−
*[[Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)]]
 
−
 
 
−
==Patient drug information==
 
−
No information available.
 
−
 
 
−
==References==
 
−
<references/>
 

Latest revision as of 13:10, 18 December 2013

Redirect to:

Retrieved from "https://hemonc.org/w/index.php?title=Obinutuzumab_(GA101)&oldid=4140"